Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioScience Health InnovationsBHIC -3.85%49 Debt-to-Equity is 0.14 as of Jun. 2026, which is 22% below its 10-year median of 0.18. GuruFocus rates BHIC with a GF Score™ of 49/100 and a GF Value™ of $121.85 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 557 Healthcare Providers & Services companies, BioScience Health Innovations ranks better than 75.04% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioScience Health Innovations's Debt-to-Equity or its related term are showing as below:
BHIC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6 Med: 0.18 Max: 3
Current: 0.14
During the past 7 years, the highest Debt-to-Equity Ratio of BioScience Health Innovations was 3.00. The lowest was -6.00. And the median was 0.18.
BHIC's Debt-to-Equity is ranked better than 75.04% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs BHIC: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioScience Health Innovations Debt-to-Equity Related Terms
BioScience Health Innovations Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations Debt-to-Equity Chart
BHIC vs PETS, SCNX, HEWA: Debt-to-Equity Comparison
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations (BHIC) has a Debt-to-Equity of 0.14 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioScience Health Innovations and its competitors. This is 22% below median its historical median of 0.18. According to the industry distribution chart, BioScience Health Innovations ranks #139 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 25%.
Is BioScience Health Innovations' Debt-to-Equity too high?
BioScience Health Innovations' current Debt-to-Equity of 0.14 is 22% below median its 10-year median of 0.18. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. BioScience Health Innovations' value of 0.14 is 66.7% below this industry median. Based on the distribution chart, BioScience Health Innovations ranks #139 out of 557 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Debt-to-Equity compare to PETS and SCNX?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #139 out of 557 companies for Debt-to-Equity. This places BioScience Health Innovations in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.42. BioScience Health Innovations' value of 0.14 is 66.7% below this benchmark. While the company's 10-year median is 0.18 vs. the industry median of 0.42, BioScience Health Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current Debt-to-Equity of 0.14 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current Debt-to-Equity is 0.14, which is 22% below median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $121.85, compared to a current price of $5.00 — trading 95.9% below its estimated fair value. The current Debt-to-Equity is 0.14, which is 22% below median its 10-year median of 0.18 and 66.7% below the Healthcare Providers & Services industry median of 0.42. BioScience Health Innovations' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Debt-to-Equity is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $5.00 is trading 95.9% below its estimated GF Value™ of $121.85.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
Debt-to-Equity: 0.14 (22% below median its 10-year median of 0.18)
GF Value™: $121.85 vs. price of $5.00 (95.9% below fair value)
Industry Position: 66.7% below the Healthcare Providers & Services median (#139 of 557)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
49GF Score
Get the complete analysis for BHIC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
